Latest research on Prolia

Denosumab is a novel, fully human IgG2 monoclonal antibody specific to receptor activator of nuclear factor kappa-B ligand (RANKL), suppresses bone resorption markers in patients with a variety of metastatic tumors and is being investigated in multiple clinical trials for the prevention and treatment of bone metastases. Chemically, it consists of 2 heavy and 2 light chains. Each light chain consists of 215 amino acids. Each heavy chain consists of 448 amino acids with 4 intramolecular disulfides. FDA approved on June 1, 2010.

Prolia side effects

Prolia is not expected to cause such severe hypocalcemia due to the low dose at six-month intervals. [source, 2014]
Xgeva, on the other hand, might be expected to cause more hypocalcemia since it is given at a higher dose and more frequently. [source, 2014]
Denosumab (Prolia, XGEVA), a monoclonal antibody against RANKL, was recently demonstrated to significantly increase time to SRE compared to a bisphosphonate, Zoledronic acid, in breast and prostate cancer patients with bone disease [43, 44]. [source, 2014]
However, denusomab (humanized anti-RANKL antibody, Prolia, Amgen, USA) also has been demonstrated to cause osteonecrosis specifically of the jaw (ONJ) [4-6]. [source, 2010]